alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5320 Properdin factor B immunological test system. ( a ) *Identification.* A properdin factor B immunological test system is a device that consists of the reagents used to measure by immunochemical techniques properdin factor B in serum and other body fluids. The deposition of properdin factor B in body tissues or a corresponding depression in the amount of properdin factor B in serum and other body fluids is evidence of the involvement of the alternative to the classical pathway of activation of complement (a group of plasma proteins which cause the destruction of cells which are foreign to the body). Measurement of properdin factor B aids in the diagnosis of several kidney diseases, e.g., chronic glomerulonephritis (inflammation of the glomeruli of the kidney), lupus nephritis (kidney disease associated with a multisystem autoimmune disease, systemic lupus erythematosus), as well as several skin diseases, e.g., dermititis herpetiformis (presence of vesicles on the skin that burn and itch), and pemphigus vulgaris (large vesicles on the skin). Other diseases in which the alternate pathway of complement activation has been implicated include rheumatoid arthritis, sickle cell anemia, and gram-negative bacteremia.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 63 FR 59227, Nov. 3, 1998]
38909.

#### McMAHON v. FOLDS *et al.*

Townsend, Presiding Judge.

The bill of exceptions in this case, after reciting the final judgment of the court, states merely that “Plaintiff disagrees with this ruling.” A bill of exceptions containing no assignment of error cannot be entertained by this court. *Lawson v. Brown,*31 Ga. App. 302 (120 SE 550). Examination of the record in the *Lawson*case shows that it recited only: “The judgment in said case was adverse to petitioner and he is dissatisfied therewith.” In neither case does the bill of exceptions “specify plainly . . . the alleged error” as required by *Code Ann.*§ 6-901, and the motion to dismiss the bill of exceptions is therefore meritorious.

*126Decided June 22, 1961

Rehearing denied July 7, 1961.

*A. B. Parker,*for plaintiff in error.

*O. W. Roberts, Jr.,*contra.

*Writ of error dismissed.*

*Frankum and Jordan, JJ., concur.*
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7739 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7739

 To require the implementation of the Migrant Protection Protocols at 
               the northern border of the United States.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 20, 2024

Mr. Babin (for himself, Mrs. Miller of Illinois, Mr. Biggs, Mr. Ogles, 
    Mr. Posey, Mr. Self, Mr. Baird, Mr. Cline, Mr. Tiffany, and Mr. 
  Grothman) introduced the following bill; which was referred to the 
                       Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
 To require the implementation of the Migrant Protection Protocols at 
               the northern border of the United States.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Remain in Canada Act of 2024''.

SEC. 2. IMPLEMENTATION OF MPP AT THE NORTHERN BORDER.

    The Secretary of Homeland Security shall, as of the date of 
enactment of this Act, begin implementation of the Migrant Protection 
Protocols in accordance with the memorandum of Secretary of Homeland 
Security Nielsen entitled ``Policy Guidance for Implementation of the 
Migrant Protection Protocols'', dated January 25, 2019, except that 
such protocols shall be implemented with regard to the border between 
the United States and Canada.
                                 <all>
```
# C_2015046EN.01002302.xml

| 9.2.2015 | EN | Official Journal of the European Union | C 46/23 |
| --- | --- | --- | --- |

9.2.2015

EN

Official Journal of the European Union

C 46/23

---

Action brought on 20 November 2014 — European Commission v Czech Republic

(Case C-525/14)

(2015/C 046/30)

Language of the case: Czech

Parties

Parties

Applicant: European Commission (represented by: P. Němečková and G. Wilms, acting as Agents)

Applicant:

Defendant: Czech Republic

Defendant:

Form of order sought

Form of order sought

| — | declare that, by failing to recognise certain Netherlands hallmarks, in particular hallmarks of Waarborg Holland, the Czech Republic has failed to fulfil its obligations under Article 34 of the Treaty on the Functioning of the European Union; |
| --- | --- |

—

declare that, by failing to recognise certain Netherlands hallmarks, in particular hallmarks of Waarborg Holland, the Czech Republic has failed to fulfil its obligations under Article 34 of the Treaty on the Functioning of the European Union;

| — | order the Czech Republic to pay the costs. |
| --- | --- |

—

order the Czech Republic to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

| 1. | By failing to recognise certain Netherlands hallmarks, the Czech Republic is restricting the free movement of precious metals marked with those hallmarks and of objects produced from those metals. |
| --- | --- |

1.

By failing to recognise certain Netherlands hallmarks, the Czech Republic is restricting the free movement of precious metals marked with those hallmarks and of objects produced from those metals.

| 2. | Even if precious metal is hallmarked by a branch of a Netherlands hallmarking office in a third State, such products should be treated in the same way as goods originating in the European Union, in view of the fact that the precious metals are hallmarked in accordance with the Netherlands rules and are definitively released into free circulation. |
| --- | --- |

2.

Even if precious metal is hallmarked by a branch of a Netherlands hallmarking office in a third State, such products should be treated in the same way as goods originating in the European Union, in view of the fact that the precious metals are hallmarked in accordance with the Netherlands rules and are definitively released into free circulation.

| 3. | The Czech Republic has not shown that the possible restriction of the free movement of goods is appropriate for ensuring achievement of the consumer protection objective pursued and does not go beyond what is necessary for achieving it. |
| --- | --- |

3.

The Czech Republic has not shown that the possible restriction of the free movement of goods is appropriate for ensuring achievement of the consumer protection objective pursued and does not go beyond what is necessary for achieving it.

---
QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.87    
  


 
 

EXTENSION AGREEMENT    
  


Bank
of America, N.A.,

    as Administrative Agent

Attn: Suzanne Paul

231 South LaSalle Street

Chicago, Illinois 60604 


Ladies
and Gentlemen: 


        The
undersigned hereby agrees to extend, effective April 3, 2002, its Commitment and the Maturity Date under the Credit Agreement dated as of April 3, 2001 among
SOURCECORP, Incorporated, f/k/a F.Y.I. Incorporated, each of the Lenders party thereto, Bank of America, N.A., as Administrative Agent, and Banc of America Securities LLC, as sole lead arranger and
sole book agent (as the same may be amended or otherwise modified from time to time, the "Credit Agreement") for 364 days to April 2, 2005
pursuant to Section 2.1(d) of the Credit Agreement. Terms defined in the Credit Agreement are used herein as therein defined. 


        This
Extension Agreement shall be construed in accordance with and governed by the law of the State of Texas. The Extension Agreement may be signed in any number of counterparts, each of
which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 



	 	 	SUNTRUST BANK
	

 	
 	

Name:	
 	

/s/ DANIEL S. KOMITOR

	 	 	By:	 	Daniel S. Komitor

	 	 	Title:	 	Director






	Agreed and Accepted:
	

SOURCECORP, INCORPORATED, f/k/a

F.Y.I. INCORPORATED
	

By:	
 	

/s/ BARRY EDWARDS

	Name:	 	Barry Edwards

	Title:	 	EVP & CFO

	

BANK OF AMERICA, N.A., as Administrative Agent
	

By:	
 	

/s/ SUZANNE M. PAUL

	Name:	 	Suzanne M. Paul
	Title:	 	Vice President













QuickLinks



Exhibit 10.87


EXTENSION AGREEMENT
#### State of Connecticut *v.*Theodore L. Brown

*Arthur B. LaFranee,*in support of the application.

Submitted December 26, 1968

decided January 8, 1969

The application by the defendant for a stay of execution is denied.
EXHIBIT 32.b



CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of American Affordable Housing II Limited Partnership (the "Partnership") on Form 10-Q for the period ended June 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Marc N. Teal, Principal Financial Officer of the general partner of the general partner of the Partnership's general partner, C&M Management Inc., certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge, after due inquiry:



|(1) | The Report fully complies with the requirements of section 13(a)-15 or 15(d)-15 of the Securities and Exchange Act of 1934; and                         
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------
|    |                                                                                                                                                         
|(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Partnership.



|                |     |                            
|--------------- | --- | ---------------------------
|Date:           |     |                            
|August 14, 2009 | By: | /s/ Marc N. Teal           
|                |     |                            
|                |     | Marc N. Teal               
|                |     | Principal Financial Officer

A signed original of this written statement required by Section 906, or other

document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Fund and will be retained by the Fund and furnished to the Securities and Exchange Commission or its staff upon request.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1805 Vitamin A test system. ( a ) *Identification.* A vitamin A test system is a device intended to measure vitamin A in serum or plasma. Measurements obtained by this device are used in the diagnosis and treatment of vitamin A deficiency conditions, including night blindness, or skin, eye, or intestinal disorders.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2308, Jan. 14, 2000]
Accountants' Consent

The Board of Directors
Hardin Bancorp, Inc.:

We consent to the  incorporation by reference in the registration  statements on
Form S-8 of Hardin Bancorp,  Inc. of our report dated May 19, 2000,  relating to
the consolidated  balance sheets of Hardin Bancorp,  Inc. and subsidiaries as of
March 31, 2000 and 1999,  and the related  consolidated  statements of earnings,
stockholders' equity and other comprehensive  income, and cash flows for each of
the years in the three-year period ended March 31, 2000, which report appears in
the annual  report on Form 10-KSB of Hardin  Bancorp,  Inc.  for the fiscal year
ended March 31, 2000 filed pursuant to the  Securities  Exchange Act of 1934, as
amended.



/s/KPMG LLP
-----------
Kansas City, Missouri
June 28, 2000
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.3 Effective dates of requirement for premarket approval. A device included in this part that is classified into class III (premarket approval) shall not be commercially distributed after the date shown in the regulation classifying the device unless the manufacturer has an approval under section 515 of the act (unless an exemption has been granted under section 520(g)(2) of the act). An approval under section 515 of the act consists of FDA's issuance of an order approving an application for premarket approval (PMA) for the device or declaring completed a product development protocol (PDP) for the device. ( a ) Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a device that has been found substantially equivalent to such a device, has an approval under section 515 of the act FDA must promulgate a regulation under section 515(b) of the act requiring such approval, except as provided in paragraph (b) of this section. Such a regulation under section 515(b) of the act shall not be effective during the grace period ending on the 90th day after its promulgation or on the last day of the 30th full calendar month after the regulation that classifies the device into class III is effective, whichever is later. See section 501(f)(2)(B) of the act. Accordingly, unless an effective date of the requirement for premarket approval is shown in the regulation for a device classified into class III in this part, the device may be commercially distributed without FDA's issuance of an order approving a PMA or declaring completed a PDP for the device. If FDA promulgates a regulation under section 515(b) of the act requiring premarket approval for a device, section 501(f)(1)(A) of the act applies to the device.
( b ) Any new, not substantially equivalent, device introduced into commercial distribution on or after May 28, 1976, including a device formerly marketed that has been substantially altered, is classified by statute (section 513(f) of the act) into class III without any grace period and FDA must have issued an order approving a PMA or declaring completed a PDP for the device before the device is commercially distributed unless it is reclassified. If FDA knows that a device being commercially distributed may be a “new” device as defined in this section because of any new intended use or other reasons, FDA may codify the statutory classification of the device into class III for such new use. Accordingly, the regulation for such a class III device states that as of the enactment date of the amendments, May 28, 1976, the device must have an approval under section 515 of the act before commercial distribution.
[52 FR 17734, May 11, 1987]
##### 



EXHIBIT
3.1
 AMENDMENT NO. 4
TO
AMENDED AND RESTATED AGREEMENT OF LIMITED PARTNERSHIP
OF AMERICAN REAL ESTATE PARTNERS, L.P.
(A DELAWARE LIMITED PARTNERSHIP)
       Nevada Gaming Authority
 Nevada Gaming Laws
 Record Date
 1




---



##### 



Purposes and Business
    Nevada Gaming Law Dispositions
    2




---



##### 



(1)
    
    to require each such Limited Partner to,
subject to Article X, dispose of its Partnership Interest within 30
days (or such earlier date as may be required by the applicable
Nevada Gaming Authority) of the occurrence of the event described in
clause (a) or (b) above, or(2)
    
    to redeem the Partnership Interest of such
Limited Partner, on behalf of and for the account of the Partnership,
at a redemption price (the Redemption Price) equal to the lowest
of:
 (i)
    
    the market price
for such Partnership Interest on the Filing Date which,
in the case of a Depositary Unit, shall be the Unit
Price;(ii)
    
    the price at which
such Limited Partner acquired the Partnership Interest;
and(iii)
    
    such other lesser
amount as may be required by any Nevada Gaming Authority.
     Distributions
   3




---



##### 



provided however
   4




---



##### 



5




---



##### 



General PartnerAMERICAN PROPERTY INVESTORS, INC.By:
    
    /s/ John P. SaldarelliName:
    
    John P. SaldarelliTitle:
    
    Vice PresidentLimited PartnersBy: AMERICAN PROPERTY INVESTORS, INC.,(attorney-in-fact)By:
    
    /s/ John P. SaldarelliName:
    
    John P. SaldarelliTitle:
    
    Vice President
  6
### S3tZln.0i)0z 

### CfrU*-V feE Ci-vr^t^A S^fiXttJ^ 

### •April 3LS)Q6iS' C\<L*\C (&*\ frco^W <j£A UJ-.-AH ^VjTC<Vn\^V ^ GQURTOFCRIMINALAPPEALS: 

### Jp.o. R^^i^jgJS :

___ -APR 27 2015 ~Re^ *5V(v\os oP ~^b^V Cooy^nc^->u>f\ U^rA VW*>6,<> Cofpux *\Mogffjg-A 0^ msasqk-fl "w^iVr CNc?\c 

### lKe_ rcc^ocsVecL ^V^yAo^ vj^A^\c&1 CS f\**&e£l £a-^ o«v/ inn^vtlw vyasis \t>or GLSS>sW\^-e r^> esLf\preCiq;U>
^C.£lt S/ndf/A /^A^ 

### .CkrWc.C.^ V^R<CMtvc»S^ ^OKqftfoA* 

### "T^lKftAA. Ulft^pO Tv^ A^u^^- \Hoo ftwVSHS^ 

### Tr&efo^'Tx- 1^Q3
Exhibit 10.1

 

FIRST AMENDMENT TO THE 
 CLOUD PEAK ENERGY INC. 2009 LONG TERM INCENTIVE PLAN 
 (AS AMENDED AND RESTATED EFFECTIVE MARCH 3, 2017)

 

THIS FIRST AMENDMENT (the “Amendment”), dated as of May 10, 2017, to the Cloud Peak Energy Inc. 2009 Long Term Incentive Plan, as amended and restated effective March 3, 2017 (the “Plan”), as approved by the Board of Directors (the “Board”) of Cloud Peak Energy Inc. (the “Company”), is hereby adopted by the Company.

 

W I T N E S S E T H:

 

WHEREAS, the Company maintains the Plan;

 

WHEREAS, subject to certain limitations, Section 15.1 of the Plan gives the Board the authority to amend the Plan;

 

WHEREAS, the Board, based upon the recommendation of the Compensation Committee of the Board, which committee has previously been appointed by the Board pursuant to Section 3.1 to administer the Plan (the “Committee”), has determined that it is in the best interests of the Company and its subsidiaries, subject to the approval of the Company’s stockholders at the Company’s 2017 Annual Meeting of Stockholders, (1) to amend the Plan to increase the number of shares of common stock of the Company available under the Plan by an additional 1,400,000 shares from 7,100,000 shares to 8,500,000 shares and (2) to extend the term of the Plan; and

 

WHEREAS, the Company desires to make the amendment to the Plan described above.

 

NOW, THEREFORE, the Plan shall be amended effective as of the date hereof as follows:

 

1.              Section 2.43 is amended in its entirety as follows:

 

“Termination Date” means the tenth anniversary of the Company’s 2017 Annual Meeting of Stockholders on May 10, 2017.

 

2.              The second sentence of Section 4.1 is amended as follows:

 

“The aggregate number of Shares that may be made the subject of Awards or Options granted under the Plan shall not exceed, since its original inception, 8,500,000 shares (which aggregate maximum number of shares shall be comprised of the 7,100,000 shares previously available and an additional 1,400,000 shares that become available as of May 10, 2017), no more than 2,000,000 of which may be granted as Incentive Stock Options.”

 

* * *

 

Except as expressly amended herein, the Plan remains in full force and effect in accordance with its terms.

 

IN WITNESS WHEREOF, the undersigned has executed this First Amendment to the Plan, to be effective as of May 10, 2017.

 

	
 
    	
CLOUD PEAK ENERGY   INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Bryan   J. Pechersky
    
	
 
    	
Name:
    	
Bryan J.   Pechersky
    
	
 
    	
Title:
    	
Executive   Vice President, General Counsel and Corporate Secretary
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3930 *Vibrio cholerae* serological reagents. ( a ) *Identification. Vibrio cholerae* serological reagents are devices that are used in the agglutination (an antigen-antibody clumping reaction) test to identify *Vibrio cholerae* from cultured isolates derived from clinical specimens. The identification aids in the diagnosis of cholera caused by the bacterium *Vibrio cholerae* and provides epidemiological information on cholera. Cholera is an acute infectious disease characterized by severe diarrhea with extreme fluid and electrolyte (salts) depletion, and by vomiting, muscle cramps, and prostration. If untreated, the severe dehydration may lead to shock, renal failure, cardiovascular collapse, and death.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 63 FR 59227, Nov. 3, 1998]
[if !vml]>[endif]>

[if !vml]>[endif]>

You have reached the FederalDepository Library Program Electronic Collection (FDLP/EC) Archive. Thisarchive assures ongoing access to publications in the FDLP/EC. Access topublications in the archive is available through GPO's suite of cataloging andlocator services, including the Catalog of U.S. Government Publications(CGP).  Archived copies of publications are retrieved in the event thatpublications are no longer available from the original publishing agency site. 
**Title:****Short test correlation analyseson 300, 1975 model year cars**
 
Volumes: 01 | 02
 
SuDoc Number:EP 1.2:SH 8/2/VOLS.1-2
Item Number:0431-I-01 (online)
CGP systemNumber:001108618
 
October 31, 2019
### Q\e\9^voc ——RECEIVEDIN-
— 3JN^ ^\^V\X^^%QURT OF CRIMINAL APPEALS-r^SAv (LQs>.^L—^vjMSSSol FEB 17 2015 

# *T ~T^ %\frhfe Of ^YKs AbelAcosla^Ierr

## JAlgs: Cfr frft^ft^ ^ow^e^ N\g\i:ow\ -yo or^M^ -txva^ to fiv^

?^^ ^er^TiC^A TCfii. 

# T^^^JcTl^^^^_^\/T^ \M - 1&_pA^i •Tt> -Vfc V^Vi^^v^ -5o^<h^ Or frftnv (LexJ?X:



## (/\(\^CL^Y- 3&*^>\^xn&\V , PV^W&mt , ^gsft^er^AV^ t^Pit -^V^ £00vl-v -Q^Acsry .V&s Mem<\na..jm .5XTCJS&. ~XtCAg. .TD -S^S^siJb^L. I COURT OF CRiMlfelALAgEEALS—

^vVe Wvs

„ _£E& 2_o_2DJ.5_ -AberAcestarClerR' V-Vqa w>^> i^os^Wsc: om Q\OM 

### <ExtgKfi>\bwi to ... Tfs\.e_ T£^__J^xmoM.. .A^BL^.^J^t'Enoyft"?^^ «-\2_^v_S____ 

## x &e 3\M<& 

### A^SAA&w^ - _S S^\JS5>TIM^_.•___*_.-_'_^__5isJ%\Pn^ &$ ^>Q y><V^
iTUclTAO.hJ&SU _S^E_>_JS_ __^il___S__i_. 

### ^COlU A^VS £ .MTVJ^/^TtM ^g\J\^ViO 3 fr?_^UAireA^,_ X^e-f^c\A \_-\X CA.C^ Aro^

_^_3__V\-V 3__ar

_.___


### ____._ J^S^^-T^Wm.. ^u^.rno_5X._,. "s?3_3_a 

### idt^K^Uc^^A^^j^JhhOiiDt^JL Sfr/f ..--flZ /

5"7^7 7 fl_># -' £ • fc •3• O _/£0o &/M^C <S7:

rhu&rfrJ^ ''J&rtt

_ ,7 ZQAZr..

v^. <l £ H
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3661 Optical Impression Systems for CAD/CAM. ( a ) *Identification.* An optical impression system for computer assisted design and manufacturing (CAD/CAM) is a device used to record the topographical characteristics of teeth, dental impressions, or stone models by analog or digital methods for use in the computer-assisted design and manufacturing of dental restorative prosthetic devices. Such systems may consist of a camera, scanner, or equivalent type of sensor and a computer with software.
( b ) *Classification.* Class II (Special Controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of the chapter subject to the limitations in § 872.9. The special control for these devices is the FDA guidance document entitled “Class II Special Controls Guidance Document: Optical Impression Systems for Computer Assisted Design and Manufacturing (CAD/CAM) of Dental Restorations; Guidance for Industry and FDA.” For the availability of this guidance document, see § 872.1(e).
[68 FR 19738, Apr. 22, 2003]